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1078–5Objectives. To evaluate the relationship between C-Reactive Protein (hsCRP), a serum marker of inflammation, and en-
dothelial dysfunction in patients with intermittent claudication.
Design, Patients and Methods. Cross-sectional study with stratified sampling on dependent variables of age, genre, hy-
pertension, hyperlipidemia, diabetes, smoking status and ankle-brachial index (ABI) to select 156 patients from a target
population of 4,100 patients with claudication. We assessed the flow-mediated arterial dilation (FMAD) as a reporter of
endothelial function and plasma levels of hsCRP and fibrinogen.
Results. Patients with a FMAD< 3% (range for the lowest 5% of healthy subjects) had increased levels of plasma hsCRP
(6.3 vs 2.3 mg/L; p< 0.05) and fibrinogen (351vs 302 mg/L; p< 0.05) in comparison to those with FMAD> 3%. There
was a negative correlation between hsCRP and FMAD(r¼0.465; p< 0.05).
Conclusion. Impaired endothelial dysfunction is association with increased plasma concentrations of inflammatory
markers, and both may have a role in the aetiopathogenesis of peripheral arterial disease.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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markers.Introduction
We are increasingly aware that inflammation plays
a major role in the pathogenesis of peripheral arterial
disease (PAD).1 Atherosclerosis can be considered as
a chronic inflammatory disease of the arterial system.2
Moreover, recognizing the inflammatory nature of
atherosclerosis has important clinical implications.
Only 50% of the patients with PAD present with hy-
perlipidemia,3 which is the main objective of preven-
tive treatment; and the prevalence of classical risk
factors such as diabetes, smoking and high blood
pressure is only slightly higher in patients diagnosed
with coronary arterial disease (CAD) or PAD, com-
pared with patients of the same age without these dis-
eases.4 C-Reactive Protein (CRP) and fibrinogen are
non-specific plasma markers in the acute phase of in-
flammation and have been of special interest over thesponding author. Dr. J. De Haro, Hospital Universitario Ge-
ngiology and Vascular Surgery Service, C/Jacinto Verdaguer
.B 1A, 28019. Madrid, Spain.
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clude their potential direct role in the pathogenesis
of non-specific circulatory inflammation,5,6 their role
as disease markers7,8,9 and disease progression
markers1 and their use for monitoring potential treat-
ments.10 However, it has not yet been established by
which the mechanisms the high protein levels (CRP
and fibrinogen) in the acute stage of inflammation
are involved in the generation, development and se-
verity of PAD.
One of the possible mechanisms by which inflam-
mation leads to PAD could be through alteration of
the functional properties of the endothelium, trigger-
ing a series of changes that are directly related to
the onset, progression and clinical severity of athero-
sclerosis. As our group has shown,11 endothelial func-
tion can be evaluated in a reliable and simple way by
determining the arterial vasodilator response to
a pharmacological or physical stimulus, such as sus-
tained ischaemia, through the measurement of nitric
oxide levels in the brachial artery.12,13
Previous studies have noted the existence of a rela-
tionship between classical cardiovascular risk factorsr Surgery. Published by Elsevier Ltd. All rights reserved.
481Inflammatory Origin of Peripheral Arterial Disease(CVRF) (age, hypertension, diabetes, hyperlipidemia
and smoking) and reduced endothelium-mediated ar-
terial reactivity, measured in the brachial artery, even
in the absence of symptomatic atherosclerotic dis-
ease.14 Moreover, there is a positive correlation of
peripheral endothelial function, measured in the bra-
chial artery, with that in the coronary circulatory
bed.15 Further reduction of endothelial reactivity is
associated with increased cardiovascular risk.16,17 Al-
tered endothelium-mediated arterial dilation is re-
lated to a chronic low-grade inflammatory status in
patients with CAD.18,19 Therefore, the vasomotor
dysfunction of the brachial artery seems to reliably
reflect generalized endothelial dysfunction and is an
effective measurement of vulnerability to the develop-
ment of atherosclerosis. However, there are few data
either on endothelium-mediated arterial dilation in
PAD20,21,22 or on the potential role of endothelial
dysfunction in atherogenesis and its relation to the
systemic inflammatory processes.Objectives
The aim of the present study was to evaluate the pos-
sible relationship between CRP and fibrinogen plasma
levels and endothelial dysfunction in patients with
claudication of the same clinical severity and CVRF
burden,23 enabling us to understand those processes
through which inflammation acts at the beginning of
and during the progression of PAD.0
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Fig. 1. Graph of the association trend between FMAD and
CRP ( p< 0.05).Patients and Methods
The target population consisted of the 4100 patients
with ischaemic claudication cared for by our Angiol-
ogy and Vascular Surgery Service. This cross-sectional
study carried out a stratified sampling with the depen-
dent variables age, gender, hypertension, hyperlipid-
emia, diabetes, smoking status and the ankle-brachial
index (ABI) in order to rule out any confounding fac-
tors that could potentially bias the possible association
between CRP and fibrinogen plasma levels1,7,24 and
endothelial dysfunction.23 The sample included 156
patients (all male; mean age 64.8 10.2 years) from
the outpatient population at Getafe University Hospi-
tal, (Madrid, Spain). PAD had been diagnosed accord-
ing to clinical criteria and an ABI< 0.9 with one or
more stenoses of at least 50% in an artery of the lower
limbs, shown by duplex or angiography. All of the pa-
tients included in the studywere over 45 years-old and
presented with stage 2 or 3 intermittent claudication
according to the Rutherford25 scale. No patient who
had been subjected to a previous revascularizationprocedure was included in the study. We also ex-
cluded from the sample all patients diagnosed with
any chronic inflammatory disease or acute infectious
process and those who had fever physical trauma or
had undergone surgery in the previous 45 days.
The sample size necessary to detect the poss-
ible differences in plasma CRP as a function of flow-
mediated arterial dilation (FMAD) measured in the
brachial artery was determined based on the assump-
tion of a standard a error of 0.05 and assuming a statis-
tical power of 0.8 for our cross-sectional design.26 The
estimated variances for each of the variables were
taken from studies previously published on our pop-
ulation.1,11 and tables of sample size for analytical
studies.27
We collected demographic data and reviewed each
patient’s clinical record, recording: classical CVRFs,
other pertinent disease background, concomitant pa-
thologies, medication and current clinical status. A
complete physical check-up was performed at the first
visit. Within one week, ABI was determined in the
posterior tibial arteries and the dorsalis pedis arteries
of both lower limbs for each patient according to the
routine protocol of our vascular lab.
Endothelial function was evaluated in the brachial
artery using Doppler ultrasound equipment (Technos,
Esaote) as described and validated in previous stud-
ies11 and according to recent guidelines.28 The dia-
meter of the brachial artery was measured after 40
and 70 seconds of reactive hyperemia and compared
with basal measurements at rest. Reactive hyperaemia
was induced by deflating a pressure cuff placed on
the arm at a pressure of 250 mmHg for five minutes.
FMAD was expressed as a percentage of the relative
change in arterial diameter before placing and after
deflating the cuff. All the measurements were taken
in the morning, after 12 hours of fasting without med-
ication, in a quiet room and after 10 minutes of rest.Eur J Vasc Endovasc Surg Vol 35, April 2008
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Peripheral blood samples were obtained from each
patient through venous puncture, and CRP plasma
levels were determined by automated hyper-sensitive
immune-assay (Roche Diagnostics GMBH) with a low
limit detection of 0.2 mg/L and with a variation coeffi-
cient of 4.2% in 4 mg/L and of 6.3% in 1 mg/L.29 In ad-
dition, we determined in each patient the plasma lipid
profile (total cholesterol, triglyceride, HDL, LDL and
VLDL lipoprotein levels), plasma concentrations of
homocysteine, fibrinogen, creatinine and glycosylated
hemoglobin (HbA1c), as well as a full blood count.Diagnostic criteria
The CVRFs considered in this study were smoking,
hypertension, diabetes and hyperlipidemia. A patient
was considered a non-smoker only if the patient had
absolutely no history of smoking. The patient was
considered to be an ex-smoker if he had given up
the habit at least 6 months prior to inclusion into the
study. A patient was classified as hypertensive when
arterial systolic/diastolic blood pressure values were
>140/90 mmHg or the patient was taking medication
for high blood pressure. A patient was considered to
have Diabetes Mellitus if he presented with basal gly-
caemia of over 6.5 mmol/L or was being treated with
oral anti-diabetic drugs or insulin.
Hyperlipidemia was considered to be present if the
plasma concentration of total cholesterol was over
6.2 mmol/l, triglyceride levels were over 2.25 mmol/l
or the patient was taking lipid-reducing drugs.
CAD was considered to be present when the
patient’s clinical record included any episode of myo-
cardial infarctation, or a positive coronary angiogram/
isotope scan. Cerebro-vascular disease was con-
sidered present when the patient had a history of
previous ischaemic event or a stenosis of over 50%
documented by duplex or angiography in at least
one carotid artery.Statistical analysis
We used non-parametric tests for analyzing the values
of hsCRP and fibrinogen, since their distribution was
not normal. The Kolmogorov-Smirnov Test was used
to check the normal distribution of FMAD in our pop-
ulation and then analysis was carried out using the
Student T-test.
A multi-variate analysis was carried out for CVRFs,
plasma markers of acute inflammation and for anti-
inflammatory, platelet aggregation inhibitor, statinsEur J Vasc Endovasc Surg Vol 35, April 2008and angiotensin enzyme converter inhibitors (AECI)
medication to control for confounders among the
groups in each analysis. Correlation analysis was car-
ried out with the rho-Spearman uni-variate test be-
tween hsCRP and FMAD, to disclose any possible
correlation between these two variables. We used
the prevalence ratio to obtain the power of association
between hsCRP and FMAD. It is defined as the ratio
of the number of patients whose hsCRP plasma levels
were elevated (over 3 mg/L as suggested by the
American Heart Association) and in whom a FMAD
under 3% was detected (3% being the lowest 5 percen-
tile value of FMAD in healthy subjects under 30 years
studied in our laboratory) to the number of patients
with hsCRP> 3 mg/L and FMAD over 3%.
Prevalence Ratio of endothelial dysfunction in
patients with a chronic inflammatory
vascular process
¼ exposed patients
non-exposed patients
¼ patients with CRP> 3mg=L and FMAD< 3%
patients with CRP> 3mg=L and FMAD> 3%
The data are expressed as the mean  standard
deviation (in normally distributed variables) or the
median [interquartile range] (in the non-normally dis-
tributed variables). All calculations were carried out
with SPSS 11.5 (Microsoft) software. Statistical signifi-
cance was considered with a p-value of <0.05 in
2-sided tests.Results
From stratified sampling dependent on variables of
age, sex, hypertension, hyperlipidemia, diabetes,
smoking status and ABI, we obtained a sample of
156 male patients. A homogeneity test was applied
to each variable; for no variable was there a lack of ho-
mogeneity in distribution. Ischaemic heart disease
was present in 30 (20%) and cerebro-vascular disease
in 18 (12%) of the patients with intermittent
claudication.
To examine the relationship between FMAD and
CRP, we divided the patients into 2 groups. We used
a cutoff point for FMAD of 3% (lowest 5 percentile
in a healthy population). This cutoff point gives us
a threshold value for FMAD, with high specificity
(S¼ 96%; p< 0.05) and positive predictive value
(PPV¼ 95%; P< 0.05)11 for the presence of impaired
endothelial function. The demographic characteristics
of the two groups are shown in Table 1.
Table 1. Features of patients groups categorized according to FMAD in the brachial artery
FMAD< 3% (N¼ 66) FMAD> 3% (N¼ 90) p-value
hsCRP (mg/L) 6.3 [2.4; 9.1] 2.3 [0.8; 5.2] 0.02
Fibrinogen (mg/dL) 351 [261; 466] 302 [222; 341] 0.04
Age (years) 65 12 64 8 0.89
Hypertension (%) 36(54) 48(54) 0.93
SBP (mmHg) 145 15 145 13 0.92
DBP (mmHg) 83 12 84 10 0.94
Hyperlipidemia (%) 18(27) 21(23) 0.87
Cholesterol (mmol/L) 5.53 1.57 5.45 0.93 0.88
Triglycerides (mmol/L) 1.975 1.25 2.1 1.36 0.81
Diabetes (%) 21(33) 27(30) 0.79
Glycemia (mmol/L) 6.88 1.83 6.38 1.16 0.80
HbA1c (%) 6.2 1.2 6.0 1.2 0.85
Smoking (%) 27(41) 42(46) 0.76
ABI 0.66 0.19 0.65 0.15 0.78
Leucocytes (103/mL) 8231 2312 8005 2110 0.91
Creatinine (mg/dL) 1.05 0.12 0.97 0.1 0.54
Homocysteine (mmol/L) 10.88 3.1 12.87 4.5 0.61
Heart Disease (%) 15(22) 15(16) 0.55
Cerebro-vascular Disease (%) 12(18) 6(66) 0.23
Treatment
Anti-platelet (%) 48(72) 66(74) 0.77
Statins (%) 18(27) 27(30) 0.78
ACEi (%) 33(50) 48(53) 0.72
Nitrates (%) 3(5) 6(7) 0.67
Beta-blockers (%) 6(9) 6(7) 0.63
Calcium antagonist (%) 9(14) 12(13) 0.59
SBP: systolic blood pressure; DBP: diastolic blood pressure; ACEi: angiotensin enzyme converter inhibitors.
483Inflammatory Origin of Peripheral Arterial DiseaseThere were no differences in either age, prevalence
of CVRF, clinical severity, acute inflammatory markers
(other than CRP and fibrinogen), systemic atheroscle-
rotic disease, or in treatment between the 2 groups
categorized according to the FMAD threshold
(Table 1). However, in the patients with marked endo-
thelial dysfunction there were higher levels of hsCRP
(6.3 vs. 2.3 mg/L; p< 0.05) and fibrinogen (351 vs.
302 mg/dL; p< 0.05) compared with those with
FMAD >3%.
The plasma CRP and fibrinogen levels according
to quartile of FMAD are shown in Table 2. This em-
phasizes how these inflammatory markers increase
with deteriorating endothelial function (Fig. 1).
Again, in Table 3 we show how FMAD varies ac-
cording to quartile of plasma CRP concentration, to
support the negative relationship between these
two variables (Fig. 2).Table 2. Inflammation markers as a function of FMAD quartiles
FMAD Quartiles (%)
p25 p50
<1.6 (N¼ 39) 1.6e4.5 (N¼ 39)
hsCRP(mg/L) 7.2[1.6;11.8] 5.8[2.1;9.8]
Fibrinogen(mg/L) 398[321;476] 376[311;431]The relationship between inflammation and endo-
thelial dysfunction was supported further by the neg-
ative correlation between FMAD and the plasma
levels of hsCRP (r¼0.465; p< 0.05). (Fig. 3) The
strength of relationship between these two variables
was assessed by the prevalence ratio, 1.8 [95% CI
1.01e2.3].Discussion
During the past decade, PAD has become recognised
as an inflammatory disorder, but neither the pro-
cersses involved nor the sequence of pathogenetic
mechanisms that come together to produce the dis-
ease are known in detail.30
Alteration of normal endothelial homeostasis is
postulated as one of the inaugural events in thep75 p100 p-value
4.5e9.1 (N¼ 39) >9.1 (N¼ 39)
3.1[2.2;6.6] 1.7[0.4;3.4] 0.04
313[288;369] 297[212;320] 0.03
Eur J Vasc Endovasc Surg Vol 35, April 2008
Table 3. FMAD as a function of the hsCRP quartiles
hsCRP Quartiles (mg/L)
p25 p50 p75 p100 p-value
<1.3 (N¼ 39) 1.3e5.1 (N¼ 39) 5.1e8.9 (N¼ 39) >8.9 (N¼ 39)
FMAD(%) 8.7 0.61 7.9 0.45 4.1 0.54 1.76 0.43 0.04
16
484 J. De Haro et al.inflammatory process of plaque formation, progres-
sion and degeneration.31,32,33
Cardiovascular risk factors modify endothelial
function, even in the absence of clinical evidence for
cardiovascular disease.14 CRP levels appear to be as-
sociated with the clinical severity of PAD (our unpub-
lished data). In this study, such factors were
controlled in the design stage, by means of a stratified
sampling method. Thus, hypertension, diabetes, hy-
perlipidemia, smoking, age, gender and ABI are
evenly distributed among patients with FMAD< 3%
and those with better endothelial function. We found
plasma levels for hsCRP and fibrinogen, two key
inflammation markers in endothelial dysfunction,2
differed significantly between the two patient sub-
groups. CRP was inversely correlated with FMAD;
thus patients with higher plasma levels of hsCRP
and fibrinogen have the lowest percentage values of
FMAD. The strength of relationship of between
hsCRP and FMAD was supported by a significant
prevalence ratio of 1.8. The relationship between re-
duced FMAD and high levels of CRP and fibrinogen
was independent of age and other CVRFs. Similarly
previous studies have suggested that in PAD the asso-
ciation between altered FMAD and high levels of in-
flammatory markers is not related to classical risk
factors.21,23
Although our findings do not establish any causal
relationships, they are consistent with the hypothesis
that inflammation contributes to the alteration of en-
dothelial function in PAD. Hence the results of0
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Fig. 2. Graph of association trend between CRP and FMAD
( p< 0.05).
Eur J Vasc Endovasc Surg Vol 35, April 2008Sinisalo et al’s,18 who conclude that in CAD patients
CRP level normalization causes a parallel improve-
ment in endothelial function, become of great interest.
Verma et al.34 found that brachial artery FMAD was
not related to CRP and had a weak relationship with
classical CVRFs in a major cohort of healthy individ-
uals. This, together with the already widely proven
CRP marker forecasts function for PAD6,7,8,24 in
healthy subjects, supports the hypothesis that inflam-
mation comes before endothelial dysfunction in the
time sequence of pathogenic processes.
Recently, it has been suggested that CRP affects the
metabolism of nitric oxide (NO). Experimental in vitro
studies and the recent study by Clapp et al.35 on an in-
flammatory endothelial dysfunction model in humans
show that CRP has a direct and specific effect on en-
dothelial function by means of a prolonged increase
in the production of NO. This increases the expression
of GTP-cyclohydrolase-1, the limiting enzyme in the
synthesis of the co-factor of NO-synthetase, tetrahy-
drobiopterin, causing a deregulation of the cell-
receptors of NO, and the resulting reduction of its
effect.
On the other hand, Vita et al.36 suggest that certain
CVRFs and pro-inflammatory cytokines activate
endothelial cells to express leukocyte adhesion mole-
cules, promoting the adhesion of monocytes and
T-lymphocytes, causing an accumulation of leuko-
cytes on the vessel wall.0
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Fig. 3. Correlation between FMAD and the plasma levels
of hsCRP. (Spearman correlation coefficient r¼0,465;
p< 0.05).
485Inflammatory Origin of Peripheral Arterial DiseaseThis study adds to the weight of the association be-
tween endothelial function and inflammatory pro-
cesses in a coherent way. It has internal consistency,
since a dose-response relationship was observed (lin-
ear correlation between CRP and FMAD). It has exter-
nal consistency or repeatability, since the results are
consistent with those of other studies and finally the
results are biologically plausible. However, further
prospective studies are required to establish the cau-
sality of the relationships we have demonstrated.
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